Overview of Dr. Abida
Dr. Wassim Abida is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. He received his medical degree from Columbia University Vagelos College of Physicians and Surgeons and has been in practice 8 years. He is one of 495 doctors at Memorial Sloan Kettering Cancer Center and one of 90 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Oncology. He has more than 80 publications and over 500 citings.
Office
353 East 68th Street
New York, NY 10065
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2011 - 2014
University of Pennsylvania Health SystemResidency, Internal Medicine, 2009 - 2011
Columbia University Vagelos College of Physicians and SurgeonsClass of 2009
Certifications & Licensure
FL State Medical License 2021 - Present
NY State Medical License 2011 - 2026
NJ State Medical License 2019 - 2025
PA State Medical License 2009 - 2011- American Board of Internal Medicine Medical Oncology
Clinical Trials
- NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors Start of enrollment: 2022 Mar 29
Roles: Contact
- A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer Start of enrollment: 2024 Jun 04
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- 776 citationsGenomic correlates of clinical outcome in advanced prostate cancer.Wassim Abida, Joanna Cyrta, Glenn Heller, Davide Prandi, Joshua Armenia
Proceedings of the National Academy of Sciences of the United States of America. 2019-06-04 - 803 citationsIntegrative clinical genomics of advanced prostate cancer.Dan Robinson, Eliezer M Van Allen, Yi-Mi Wu, Nikolaus Schultz, Robert J Lonigro
Cell. 2015-05-21 - 3 citationsCombining Poly(ADP)-Ribose Polymerase Inhibitors With Abiraterone in Castration-Resistant Prostate Cancer: Is Biomarker Testing Necessary?Emmanuel S Antonarakis, Wassim Abida
Journal of Clinical Oncology. 2023-06-20
Lectures
- Genomic characteristics of deleterious BRCA1 and BRCA2 alterations and associations with baseline clinical factors in patients with metastatic castration-resistant pro...2019 ASCO Annual Meeting - 6/1/2019
- Microsatellite instability in prostate cancer and response to immune checkpoint blockade.2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Press Mentions
Expert Answers to Questions on PARP Inhibitor Combinations in Prostate CancerJune 30th, 2021- Clovis Oncology Presents Data in Advanced Prostate Cancer at ASCO 2021 Genitourinary Cancers Symposium Virtual MeetingFebruary 11th, 2021
Rubraca (Rucaparib) Approved in the U.S. As Monotherapy Treatment for Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (mCRPC)August 26th, 2020- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
